Gotowa bibliografia na temat „Antibody-toxin conjugates”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Antibody-toxin conjugates”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Antibody-toxin conjugates"
Esteva, Francisco J., Kathy D. Miller i Beverly A. Teicher. "What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?" American Society of Clinical Oncology Educational Book, nr 35 (maj 2015): e117-e125. http://dx.doi.org/10.14694/edbook_am.2015.35.e117.
Pełny tekst źródłaAhmad, Ateeq, i Kevin Law. "Strategies for designing antibody-toxin conjugates". Trends in Biotechnology 6, nr 10 (październik 1988): 246–51. http://dx.doi.org/10.1016/0167-7799(88)90056-x.
Pełny tekst źródłaGovindan, Serengulam V., i David M. Goldenberg. "New Antibody Conjugates in Cancer Therapy". Scientific World JOURNAL 10 (2010): 2070–89. http://dx.doi.org/10.1100/tsw.2010.191.
Pełny tekst źródłaLiang, X. P., M. E. Lamm i J. G. Nedrud. "Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus." Journal of Immunology 141, nr 5 (1.09.1988): 1495–501. http://dx.doi.org/10.4049/jimmunol.141.5.1495.
Pełny tekst źródłaPanjideh, Hossein, Nicole Niesler, Alexander Weng i Hendrik Fuchs. "Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861". Toxins 14, nr 7 (13.07.2022): 478. http://dx.doi.org/10.3390/toxins14070478.
Pełny tekst źródłaFaria, Morse, Marlking Peay, Brandon Lam, Eric Ma, Moucun Yuan, Michael Waldron, William Mylott, Meina Liang i Anton Rosenbaum. "Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2". Antibodies 8, nr 1 (11.01.2019): 11. http://dx.doi.org/10.3390/antib8010011.
Pełny tekst źródłaYu, Rui, Junjie Xu, Tao Hu i Wei Chen. "The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity". Mediators of Inflammation 2020 (4.07.2020): 1–11. http://dx.doi.org/10.1155/2020/9596129.
Pełny tekst źródłaMarsh, J. W., i D. M. Neville. "A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins." Journal of Immunology 140, nr 10 (15.05.1988): 3674–78. http://dx.doi.org/10.4049/jimmunol.140.10.3674.
Pełny tekst źródłaGovindan, Serengulam V., Gary L. Griffiths, Hans J. Hansen, Ivan D. Horak i David M. Goldenberg. "Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies". Technology in Cancer Research & Treatment 4, nr 4 (sierpień 2005): 375–91. http://dx.doi.org/10.1177/153303460500400406.
Pełny tekst źródłaLefeber, Dirk J., Barry Benaissa-Trouw, Johannes F. G. Vliegenthart, Johannis P. Kamerling, Wouter T. M. Jansen, Kees Kraaijeveld i Harm Snippe. "Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus pneumoniae Type 3". Infection and Immunity 71, nr 12 (grudzień 2003): 6915–20. http://dx.doi.org/10.1128/iai.71.12.6915-6920.2003.
Pełny tekst źródłaRozprawy doktorskie na temat "Antibody-toxin conjugates"
Ng, Wai-yun Louisa. "Production of variants of mitogillin with reduced IgE binding activity". Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31972093.
Pełny tekst źródłaNg, Wai-yun Louisa, i 吳慧欣. "Production of variants of mitogillin with reduced IgE bindingactivity". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31972093.
Pełny tekst źródłaKwok, Hon Hung. "Immunolesioning in the rat brain". HKBU Institutional Repository, 1999. http://repository.hkbu.edu.hk/etd_ra/234.
Pełny tekst źródła"Construction of a Recombinant Immunotoxin". University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/2100/270.
Pełny tekst źródła"Construction of a recombinant immunotoxin". Thesis, University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/10453/20069.
Pełny tekst źródłaIn recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology. In general, this involves fusion of a toxin gene with sequence encoding a variety of clinically relevant proteins or peptides. Using these techniques a recombinant immunotoxin has been engineered by fusing the genes encoding an antibody fragment with the sequence of a small cytolytic peptide, melittin. The antibody fragment consists of the antigen binding site derived from a murine monoclonal antibody K- 1-21, which binds to human free kappa light chains and recognises a specific epitope (KMA) expressed on the surface of human myeloma and lymphoma cells. The toxic portion of the molecule is melittin, a 26 amino acid, membrane lytic peptide which is a major component of bee venom. Using PCR a single chain Fv (scFv) was constructed by linking VH and VL genes with an oligonucleotide encoding a flexible, hydrophilic peptide. The melittin gene was synthesised as an oligonucleotide and extended by PCR. Nucleotide sequence encoding a linker peptide was added to the 5' end and a primer encoding a FLAG peptide was used to extend the 3' end. This gene construct was then ligated into the recombinant expression vector, pPOW scFv, to create the fusion gene encoding the recombinant immunotoxin. The gene construct was expressed in the periplasm of E.coli (TOPP2) using the secretion signal pelB . Expression of the foreign protein was monitored by western blot using a monoclonal antibody which recognises the FLAG peptide encoded at the carboxy terminal region of the gene construct. Expression of the recombinant immunotoxin was optimised and the resulting protein was purified using anti-FLAG M2 affinity chromatography. Antigen binding activity was assessed by ELISA and flow cytometry using a human myeloma cell line, HMy2, which expresses the KMA antigen.Binding of the immunotoxin to a control human cell line, K562, which does not express KMA on the cell surface was also assessed. The results indicated that the recombinant immunotoxin retained antigen binding specificity and it was cytotoxic towards the target cell line (HMy2).
XU, HAO-JI, i 徐鎬基. "Studies on immunotoxin-monoclonal antibody 9.5D-abrin toxin a chain conjugates-against the grith of human cervical cancer cell lines". Thesis, 1991. http://ndltd.ncl.edu.tw/handle/82906099079103529855.
Pełny tekst źródłaKsiążki na temat "Antibody-toxin conjugates"
Mark, Chamow Steven, i Ashkenazi Avi, red. Antibody fusion proteins. New York: Wiley-Liss, 1999.
Znajdź pełny tekst źródłaE, Frankel Arthur, red. Immunotoxins. Boston: Kluwer Academic Publishers, 1988.
Znajdź pełny tekst źródłaPhan, Văn Chi. Trichobakin và Immunotoxin tái tổ hợp. Hà Nội: Nhà xuất bản Khoa học tự nhiên và công nghệ, 2008.
Znajdź pełny tekst źródłaRamakrishnan, S. Cytotoxic conjugates. Austin: R.G. Landes Co., 1993.
Znajdź pełny tekst źródła1960-, Tyle Praveen, i Ram Bhanu P. 1951-, red. Targeted therapeutic systems. New York: Dekker, 1990.
Znajdź pełny tekst źródła1947-, Wiley Ronald G., i Lappi Douglas A, red. Molecular neurosurgery with targeted toxins. Totowa, N.J: Humana Press, 2005.
Znajdź pełny tekst źródłaA, Lappi Douglas, red. Suicide transport and immunolesioning. Austin: R.G. Landes, 1994.
Znajdź pełny tekst źródłaFrankel, Arthur E. Immunotoxins. Springer, 2012.
Znajdź pełny tekst źródłaImmunotoxin Methods and Protocols. Humana Press, 2001.
Znajdź pełny tekst źródłaFrankel, A. Clinical Applications of Immunotoxins (Current Topics in Microbiology and Immunology). Springer-Verlag Telos, 1998.
Znajdź pełny tekst źródłaCzęści książek na temat "Antibody-toxin conjugates"
Cumber, Alan J., i Edward J. Wawrzynczak. "Preparation of Cytotoxic Antibody—Toxin Conjugates". W Immunochemical Protocols, 135–44. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-59259-257-9_13.
Pełny tekst źródłaPietersz, Geoffrey, i Ian McKenzie. "Immunotherapy for Cancer—Toxin-Antibody Conjugates". W Toxins and Targets, 65–74. London: Routledge, 2022. http://dx.doi.org/10.4324/9781315076911-8.
Pełny tekst źródłaNeville, David M. "Monoclonal Antibody Mediated Drug Delivery and Antibody Toxin Conjugates". W Directed Drug Delivery, 211–30. Totowa, NJ: Humana Press, 1985. http://dx.doi.org/10.1007/978-1-4612-5186-6_12.
Pełny tekst źródłaBlakey, David C., Edward J. Wawrzynczak, Philip M. Wallace i Philip E. Thorpe. "Antibody Toxin Conjugates: A Perspective (Part 1 of 2)". W Monoclonal Antibody Therapy, 50–70. Basel: KARGER, 1988. http://dx.doi.org/10.1159/000318800.
Pełny tekst źródłaBlakey, David C., Edward J. Wawrzynczak, Philip M. Wallace i Philip E. Thorpe. "Antibody Toxin Conjugates: A Perspective (Part 2 of 2)". W Monoclonal Antibody Therapy, 71–90. Basel: KARGER, 1988. http://dx.doi.org/10.1159/000318801.
Pełny tekst źródłaWawrzynczak, Edward J., i Alan J. Cumber. "Immunoaffinity Purification and Quantification of Antibody—Toxin Conjugates". W Immunochemical Protocols, 145–53. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-59259-257-9_14.
Pełny tekst źródłaOhtani, Katsumi, i Yoshio Ueno. "Selective Antitumor Activity of T-2 Toxin-Antibody Conjugates". W Microbial Toxins in Foods and Feeds, 403–9. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-0663-4_38.
Pełny tekst źródłaColombatti, M., M. Bisconti, P. Lorenzi, G. Stevanoni, B. Dipasquale, M. Gerosa i G. Tridente. "Human Glioma Cell Lines: Tumour Associated Antigens Distribution and Sensitivity to Antibody-Toxin or Ligand-Toxin Conjugates. A Preliminary Report". W Proceedings of the 8th European Congress of Neurosurgery, Barcelona, September 6–11, 1987, 121–25. Vienna: Springer Vienna, 1988. http://dx.doi.org/10.1007/978-3-7091-8978-8_26.
Pełny tekst źródłaOldham, Robert K. "Antibody-Drug and Antibody-Toxin Conjugates". W Immunity to Cancer, 575–85. Elsevier, 1985. http://dx.doi.org/10.1016/b978-0-12-586270-7.50053-7.
Pełny tekst źródła"Antibody Toxin Fusions or Conjugates". W Encyclopedia of Cancer, 268. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-46875-3_100201.
Pełny tekst źródłaStreszczenia konferencji na temat "Antibody-toxin conjugates"
Terrett, Jonathan A., Rachel Dusek, Dee Aud, Rahel Awdew, Sudha Swaminathan, San Lin Lou, Michael Trang i in. "Abstract 661: Proteomics and selecting the right combination of target and toxin for antibody-drug-conjugate (ADC) development". W Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-661.
Pełny tekst źródłaRickles, Richard J., Thomas P. Giordano, Shakira F. Cotard, Jill M. Grenier, Angela Romanelli i Ti Cai. "Abstract 4765: Drug synergies observed for antibody and toxin components of SAR3419 ADC contribute to overall conjugate efficacy and can be combination drug or tumor cell line dependent". W Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4765.
Pełny tekst źródła